-

SAI MedPartners Acquires PharmaForce

READING, Pa.--(BUSINESS WIRE)--SAI MedPartners (“SAI”), a leading consultancy providing strategic insights and analytics to the pharmaceutical, biotechnology, and medical device industries, is pleased to announce it has acquired PharmaForce International (“PharmaForce”). Northlane Capital Partners (“NCP”) partnered with management to acquire SAI in June 2022.

PharmaForce, headquartered in Reading, PA, is a market intelligence firm that focuses on analyzing the sales, marketing, market access, and medical affairs activities of leading pharmaceutical and biotech companies primarily through syndicated research reports. PharmaForce’s offerings allow its clients to better understand the commercial operations of their competitors, enabling enhanced strategic decision-making. The PharmaForce team will constitute SAI’s Syndicated Offering division.

“We are delighted to welcome PharmaForce to the SAI family, further enhancing our competitive intelligence (“CI”) capabilities. PharmaForce’s commercial benchmarking offerings complement our core CI services by providing supplemental data and incremental insights to our customers,” said Erik Nordhoy, Founder and CEO of SAI.

Greg Yoder, COO of PharmaForce, commented “We are very excited to be joining the SAI team. We look forward to continuing to provide CI services to our client base, while expanding our reach and breadth of offerings through the existing SAI network and platform.”

ABOUT SAI MEDPARTNERS

SAI is a leading consultancy providing strategic insights and analytics to the pharmaceutical, biotechnology, and medical device industries. Headquartered in Reading, Pennsylvania, SAI provides best-in-class competitive intelligence and strategy support services to assist its clients across the product development lifecycle. SAI works with leading multinational pharmaceutical companies, in addition to a growing number of biotechnology and medical device companies. SAI has a presence across the United States, Europe, and Asia. For more information, please visit www.sai-med.com.

ABOUT NORTHLANE CAPITAL PARTNERS

Based in Bethesda, MD, NCP is a middle market private equity firm focused on key segments within the healthcare and business services sectors, where its principals have invested more than $1.6 billion of equity capital. NCP’s strategy is to partner with industry leading companies and great management teams, aligning incentives to accelerate growth and build value. For more information, please visit www.northlanecapital.com.

Contacts

SAI CONTACT

Erik Nordhoy, CEO
(610) 685-4204

NCP CONTACTS

Eugene Krichevsky, Partner
(301) 841-1399

Justin DuFour, Partner
(301) 841-1375

JJ Carbonell, Principal
(301) 841-1420

Anna Ellingboe, Vice President
(301) 272-9992

Northlane Capital Partners


Release Versions

Contacts

SAI CONTACT

Erik Nordhoy, CEO
(610) 685-4204

NCP CONTACTS

Eugene Krichevsky, Partner
(301) 841-1399

Justin DuFour, Partner
(301) 841-1375

JJ Carbonell, Principal
(301) 841-1420

Anna Ellingboe, Vice President
(301) 272-9992

More News From Northlane Capital Partners

SAI MedPartners Enhances Its Competitive Intelligence Capabilities Through the Acquisition of The Dunn Group

READING, Pa.--(BUSINESS WIRE)--SAI MedPartners (“SAI”), a global consultancy providing strategic insights and analytics to the pharmaceutical, biotechnology, and medical device industries, is pleased to announce that it has acquired The Dunn Group (“TDG”). Northlane Capital Partners (“NCP”) partnered with management to acquire SAI in June 2022. TDG, headquartered in Totowa, NJ, is a competitive intelligence firm that focuses on providing primary business intelligence to clients in the pharmaceu...

Northlane Capital Partners Announces Final Close of Oversubscribed Fund III at $750 Million

BETHESDA, Md.--(BUSINESS WIRE)--Northlane Capital Partners (“Northlane” or “NCP”) announced today the final closing of its oversubscribed third private equity fund, Northlane Capital Partners III LP (“NCP III” or “Fund III”), at its hard cap of $750 million. The total raised substantially surpassed Fund III’s $550 million target and reflects notable growth from its $408 million predecessor. Global investors include pension funds, insurance companies, endowments and foundations, asset managers,...

Northlane Capital Partners Announces the Sale of Empower Community Care

BETHESDA, Md.--(BUSINESS WIRE)--Northlane Capital Partners (“NCP”) announced today the sale of Empower Community Care (“Empower” or the “Company”) to NexPhase Capital, LP (“NexPhase”). Founded in 2016, Empower is an established global behavioral health organization offering proprietary treatments and services to help at-risk youth, their families, and caregivers. The Company does not directly administer the treatment but instead provides its state and municipal clients with training and support...
Back to Newsroom